NCT07582237Active, not recruiting
Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 262 (actual)
- First submitted
- 6 May 2026
- Start date
- 5 Oct 2021
- Primary completion date
- 21 Aug 2028
- Lead sponsor
- Kang Stem Biotech Co., Ltd.
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07582237
What you commit to
- Study type: Observational
- Participants enrolled: 262
- From 5 Oct 2021 to the primary completion date, 21 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Those who participated in the K0106 clinical trial and received FURESTEM-AD Inj
- Those who understand and voluntarily sign an informed consent form
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bucheon Hospital, Soonchunhyang University Coordinator of this site? Confirm its status | Bucheon-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.